RESUMO
INTRODUCTION: Patient-reported outcomes (PROs) provide subjective information about their disease, treatment, and quality of life. OBJECTIVE: To introduce a new system of work coordinated between pharmacists and dermatologists, based on the collection and analysis of PROs to assess its clinical impact as well as patients satisfaction. METHOD: A prospective single-centre observational study was conducted under clinical conditions and included adult patients diagnosed with psoriasis (PS) and atopic dermatitis (AD) between April-2021 and February-2022. Pharmacists and dermatologists agreed on this systematic work. A REDCap® database was designed to facilitate data collection and the subsequent analysis. RESULTS: A total of 288 and 41 patients with PS and AD, respectively, were included. Those who started treatment showed significant improvement with a decrease in PROs and clinical parameters (p < 0.001). The pharmacist made 168 and 7 recommendations to dermatologists for PS and AD patients, respectively, of which 66.07% and 57.1% were accepted. The most common recommendations were «consult with rheumatologist¼ (20.83%), «extend drug regimen¼ (19.64%) and «consider change in treatment¼ (11.90%). Adverse events were reported in 55 and 17 patients with PS and AD, respectively. Of 103 patients, 75% were «very satisfied¼ and 20% «satisfied¼ with the system. CONCLUSIONS: This new working system helps to evaluate the short and long-term effectiveness of treatments and also to identify adverse events, alarm symptoms and co-morbidities in order to optimize therapies. Collaboration between pharmacists and dermatologists reduces decision-making time and patients appreciate better clinical care leading to higher patient satisfaction.
Assuntos
Dermatite Atópica , Dermatologia , Farmácia , Psoríase , Adulto , Humanos , Dermatite Atópica/tratamento farmacológico , Qualidade de Vida , Estudos Prospectivos , Medidas de Resultados Relatados pelo Paciente , Psoríase/tratamento farmacológicoRESUMO
Background Palbociclib and ribociclib are novel oral agents in hormone receptor-positive metastatic breast cancer. Neutropenia is a common adverse event associated with these treatments and its clinical management often requires regimen changes, such as cycle delays and dose adjustments. Objective To provide a real-world experience of the effectiveness and toxicities associated with these drugs and to evaluate the impact of regimen changes in disease progression. Setting This study was performed at Hospital Universitario La Paz, in Spain. Methods Observational, retrospective study which included hormone receptor-positive metastatic breast cancer patients who initiated treatment with palbociclib or ribociclib between March 1st, 2018 and March 1st, 2019. Main outcome measure The primary effectiveness variable was progression-free survival. Safety evaluation was performed to determine neutropenia-incidence and severity, as well as its clinical management, including dose adjustments and treatment interruptions. Correlations between these regimen changes and effectiveness were also evaluated. Results Sixty-one patients were included, 33 treated with palbociclib and 28 with ribociclib. Palbociclib was mainly used as second line of treatment in the metastatic setting (81.8%) and ribociclib as first line (67.9%). The median progression-free survival was 12.76 months (95% CI 7.5 to not estimable) in palbociclib and not reached in ribociclib. After 12 months, the progression-free survival rate was 51.5% (95% CI 34-69) in palbociclib and 78.6% (95% CI 63-94.1) in ribociclib. Neutropenia was the most common adverse event with an incidence rate of 87.9% in palbociclib and 82.1% in ribociclib. Cycle delays were needed in more than half of the patients treated with palbociclib and ribociclib (63.6% and 64.3%). Dose adjustments were seen in 42.4% and 53.6% of the patients receiving palbociclib and ribociclib, respectively. Regimen changes did not involve statistically significant differences in 12-month PFS rates in the cohort investigated. Conclusion Palbociclib and ribociclib outcomes are comparable to those reached in the phase III trials, PALOMA-3 and MONALEESA-2, respectively, and cannot be compared as they were used in different treatment settings. The toxicity profile is favourable, being neutropenia the most common adverse event, easily managed with regimen changes. Further studies are needed to confirm the observed tendency of no detrimental impact on effectiveness of these regimen changes.
Assuntos
Neoplasias da Mama , Aminopiridinas , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Neoplasias da Mama/tratamento farmacológico , Neoplasias da Mama/epidemiologia , Feminino , Humanos , Piperazinas , Purinas , Piridinas , Estudos RetrospectivosAssuntos
Amitriptilina/efeitos adversos , Analgésicos/efeitos adversos , Hemartrose/induzido quimicamente , Agregação Plaquetária/efeitos dos fármacos , Acetaminofen/administração & dosagem , Acetaminofen/uso terapêutico , Adulto , Amitriptilina/administração & dosagem , Amitriptilina/uso terapêutico , Analgésicos/administração & dosagem , Analgésicos/uso terapêutico , Desamino Arginina Vasopressina/uso terapêutico , Epinefrina/farmacologia , Feminino , Fentanila/administração & dosagem , Fentanila/uso terapêutico , Humanos , Articulação do Joelho/cirurgia , Dor Pós-Operatória/tratamento farmacológico , Testes de Função Plaquetária , Serotonina/fisiologia , Ácido Tranexâmico/uso terapêutico , Doenças de von Willebrand/complicações , Doenças de von Willebrand/tratamento farmacológicoRESUMO
Biotecnological drugs represents the future treatment in medicine. Since the expiry of the patent of the fi rst approved biotech drug, "copying" and marketing of them can be offered by any other biotech company, these new medicines are known as biosimilar medicines. They are approved by the EMEA (European Medicines Evaluation Agency) through the European centralised procedure, the EMEA issued several stringent guidelines to approve a biosimilar drug on the European market, preclinical and clinical studies are necessary to asses the highest standards in quality, efficacy and patient safety. The World Health Organization has determined that biosimilar have the same INN than the original product.
Assuntos
Medicamentos Biossimilares , Aprovação de Drogas/legislação & jurisprudência , Legislação de Medicamentos/tendências , Medicamentos Biossimilares/efeitos adversos , Medicamentos Biossimilares/uso terapêutico , União Europeia , HumanosAssuntos
Antifúngicos/efeitos adversos , Toxidermias/etiologia , Pentamidina/efeitos adversos , Síndrome da Imunodeficiência Adquirida/complicações , Adulto , Toxidermias/prevenção & controle , Feminino , Antagonistas dos Receptores Histamínicos H1/uso terapêutico , Humanos , Hidroxizina/uso terapêutico , Injeções Intravenosas , Masculino , Pneumonia por Pneumocystis/prevenção & controleAssuntos
Antineoplásicos/efeitos adversos , Medicamentos Biossimilares/uso terapêutico , Neoplasias/complicações , Neutropenia/induzido quimicamente , Neutropenia/tratamento farmacológico , Antineoplásicos/uso terapêutico , Consenso , Europa (Continente) , Humanos , Neoplasias/tratamento farmacológico , Serviço de Farmácia HospitalarRESUMO
OBJECTIVE: To report a case of hyperglycemia induced by megestrol acetate in a patient with AIDS. CASE SUMMARY: A 28-year-old man with AIDS developed hyperglycemia requiring insulin therapy 5 days after beginning megestrol therapy. The hyperglycemia resolved with discontinuation of the agent and treatment with insulin, and recurred 2 years later, when megestrol acetate treatment was rechallenged. In this case the patient had developed hyperglycemia and pancreatitis 1 year before, related to pentamidine therapy. DISCUSSION: To our knowledge this is the first reported case of hyperglycemia that was induced by megestrol acetate as early as 5 days after beginning therapy and confirmed by rechallenge. The mechanism of action is unclear. CONCLUSIONS: Clinicians caring for patients with AIDS-related cachexia should be aware that megestrol acetate can cause a severe but reversible hyperglycemic state.